Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
|Podcasts|August 24, 2020
Speaking of Urology: How to get started with HIFU for prostate cancer
Author(s)Urology Times staff
In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.
Advertisement
Listen to the rest of this interview:
Advertisement
Related to this article
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
2
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
3
Matching mCSPC treatment to the patient, not just the trial data
4
Urocross Expander System enters US commercial use for symptomatic BPH
5